Association between Empagliflozin Use and Electrocardiographic Changes

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• Empagliflozin is a sodium-glucose transporter 2 inhibitor used for diabetes.
• Previous studies in mice suggest empagliflozin interacts with cardiac sodium channels.
• The clinical implications of these interactions on human cardiac function are not fully understood.

Purpose of the Study:

• To investigate the electrocardiographic (ECG) changes associated with empagliflozin initiation in patients with diabetes mellitus.
• To determine if empagliflozin affects cardiac repolarization or conduction in a clinical setting.

Main Methods:

• A prospective study involving 101 patients with diabetes mellitus initiating empagliflozin therapy.
• Electrocardiographic parameters, including QRS duration, were measured before and after empagliflozin initiation.
• Statistical analysis was performed to compare ECG features pre- and post-treatment.

Main Results:

• Empagliflozin use was associated with a statistically significant increase in QRS duration.
• This effect was particularly notable in the subgroup of patients with concomitant heart failure.
• No significant changes were observed in other major ECG parameters.

Conclusions:

• Empagliflozin may influence cardiac conduction, leading to prolonged QRS duration in diabetic patients.
• The observed effect is more pronounced in patients with heart failure, warranting further investigation.
• These findings highlight the importance of monitoring ECG parameters in patients receiving empagliflozin, especially those with pre-existing cardiac conditions.